HomeComparePCHUY vs ABBV

PCHUY vs ABBV: Dividend Comparison 2026

PCHUY yields 1.13% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $82.4K in total portfolio value
10 years
PCHUY
PCHUY
● Live price
1.13%
Share price
$4.88
Annual div
$0.06
5Y div CAGR
-46.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.9K
Annual income
$0.22
Full PCHUY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PCHUY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPCHUYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PCHUY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PCHUY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PCHUY
Annual income on $10K today (after 15% tax)
$96.31/yr
After 10yr DRIP, annual income (after tax)
$0.19/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,055.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PCHUY + ABBV for your $10,000?

PCHUY: 50%ABBV: 50%
100% ABBV50/50100% PCHUY
Portfolio after 10yr
$61.1K
Annual income
$12,385.99/yr
Blended yield
20.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PCHUY
No analyst data
Altman Z
1.4
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PCHUY buys
0
ABBV buys
0
No recent congressional trades found for PCHUY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPCHUYABBV
Forward yield1.13%3.06%
Annual dividend / share$0.06$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-46.5%40.6%
Portfolio after 10y$19.9K$102.3K
Annual income after 10y$0.22$24,771.77
Total dividends collected$131.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PCHUY vs ABBV ($10,000, DRIP)

YearPCHUY PortfolioPCHUY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,761$60.62$11,550$430.00$789.00ABBV
2$11,546$32.61$13,472$627.96$1.9KABBV
3$12,372$17.50$15,906$926.08$3.5KABBV
4$13,248$9.37$19,071$1,382.55$5.8KABBV
5$14,180$5.02$23,302$2,095.81$9.1KABBV
6$15,175$2.69$29,150$3,237.93$14.0KABBV
7$16,239$1.44$37,536$5,121.41$21.3KABBV
8$17,377$0.77$50,079$8,338.38$32.7KABBV
9$18,593$0.41$69,753$14,065.80$51.2KABBV
10$19,895$0.22$102,337$24,771.77$82.4KABBV

PCHUY vs ABBV: Complete Analysis 2026

PCHUYStock

PTT Public Company Limited, together with its subsidiaries, operates as a petroleum and petrochemical company in Thailand, other Asian countries, Europe, the United States, and internationally. It operates through Upstream Petroleum and Natural Gas Business Group, Downstream Petroleum Business Group, and New Business and Infrastructure Group. The company is involved in the exploration and production of petroleum; and natural gas procurement, pipeline transmission, distribution, and separation activities. In addition, it engages in the exploration, production, and distribution of coal; and marketing of petroleum products and lube oil through an operating system of procurement, storage, and distribution of products, as well as the retail business at service stations. Further, the company imports and exports petroleum and petrochemical products, as well as other related products; produces and distributes electricity, steam, and water for industrial purpose; and offers project management, human resource support, petroleum related technology, consultant management, technical consultant for electricity businesses, petrol station and convenience store management, factory maintenance and engineering, oil and gas, safety and environmental, and business services, as well as services for the storage and handling of liquid chemicals. Additionally, it invests in liquefied natural gas business; produces and distributes chilled water/constructs and installs electricity generating systems; develops electricity power production projects; develops, markets, and distributes polymers products, by products, and other polymers-related products; develops real estate properties; operates vocational schools; and manufactures and distributes biochemical products, paraxylene, and industrial coatings and additives, as well as engages in the transportation, warehouse, and bagging packing management of polyethylene. The company was founded in 1978 and is headquartered in Bangkok, Thailand.

Full PCHUY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PCHUY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PCHUY vs SCHDPCHUY vs JEPIPCHUY vs OPCHUY vs KOPCHUY vs MAINPCHUY vs JNJPCHUY vs MRKPCHUY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.